Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate

Elisabetta Cenni, Donatella Granchi, Sofia Avnet, Caterina Fotia, Manuela Salerno, Dorotea Micieli, Maria G. Sarpietro, Rosario Pignatello, Francesco Castelli, Nicola Baldini

Research output: Contribution to journalArticle

Abstract

Nanoparticles made of a conjugate of poly(d,l-lactide-co-glycolide) with alendronate (PLGA-ALE NPs), were prepared by emulsion/solvent evaporation technique. The conjugation yield, determined by MALDI TOF analysis, was 30-35%. PLGA-ALE NPs size, evaluated by photon correlation spectroscopy, was 198.7 ± 0.2 nm. Haemocompatibility studies using different concentrations of PLGA-ALE NPs did not show any significant effect on haemolysis, leukocyte number, platelet activation, APTT and complement consumption, in comparison with blood incubated with phosphate buffered saline (PBS). A significant reduction of the prothrombin activity was demonstrated after incubation with 560 μg/ml of PLGA-ALE NPs; a significant increase was observed at the highest dilutions. The viability of human umbilical vein endothelial cells and bone marrow stromal cells (BMSC), evaluated through the neutral red test, was not affected by PLGA-ALE NPs. There were no significant differences in cell-associated alkaline phosphatase between BMSC incubated with PLGA-ALE NP- and PBS-added media. These results demonstrated that PLGA-ALE NPs had an acceptable degree of blood compatibility and were not cytotoxic; therefore, they may be considered suitable for intravenous administration.

Original languageEnglish
Pages (from-to)1400-1411
Number of pages12
JournalBiomaterials
Volume29
Issue number10
DOIs
Publication statusPublished - Apr 2008

Fingerprint

Alendronate
Biocompatibility
Nanoparticles
Bone
Phosphates
Blood
Photon correlation spectroscopy
Phosphatases
Endothelial cells
Platelets
Dilution
Emulsions
Evaporation
Chemical activation
Mesenchymal Stromal Cells
Neutral Red
Matrix-Assisted Laser Desorption-Ionization Mass Spectrometry
Human Umbilical Vein Endothelial Cells
Platelet Activation
Prothrombin

Keywords

  • Bisphosphonate
  • Blood compatibility
  • Drug delivery
  • Nanoparticle
  • Poly(lactic-co-glycolic acid) copolymer

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate. / Cenni, Elisabetta; Granchi, Donatella; Avnet, Sofia; Fotia, Caterina; Salerno, Manuela; Micieli, Dorotea; Sarpietro, Maria G.; Pignatello, Rosario; Castelli, Francesco; Baldini, Nicola.

In: Biomaterials, Vol. 29, No. 10, 04.2008, p. 1400-1411.

Research output: Contribution to journalArticle

Cenni, E, Granchi, D, Avnet, S, Fotia, C, Salerno, M, Micieli, D, Sarpietro, MG, Pignatello, R, Castelli, F & Baldini, N 2008, 'Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate', Biomaterials, vol. 29, no. 10, pp. 1400-1411. https://doi.org/10.1016/j.biomaterials.2007.12.022
Cenni, Elisabetta ; Granchi, Donatella ; Avnet, Sofia ; Fotia, Caterina ; Salerno, Manuela ; Micieli, Dorotea ; Sarpietro, Maria G. ; Pignatello, Rosario ; Castelli, Francesco ; Baldini, Nicola. / Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate. In: Biomaterials. 2008 ; Vol. 29, No. 10. pp. 1400-1411.
@article{e7faf43e8646438dabf3d14dc9264d42,
title = "Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate",
abstract = "Nanoparticles made of a conjugate of poly(d,l-lactide-co-glycolide) with alendronate (PLGA-ALE NPs), were prepared by emulsion/solvent evaporation technique. The conjugation yield, determined by MALDI TOF analysis, was 30-35{\%}. PLGA-ALE NPs size, evaluated by photon correlation spectroscopy, was 198.7 ± 0.2 nm. Haemocompatibility studies using different concentrations of PLGA-ALE NPs did not show any significant effect on haemolysis, leukocyte number, platelet activation, APTT and complement consumption, in comparison with blood incubated with phosphate buffered saline (PBS). A significant reduction of the prothrombin activity was demonstrated after incubation with 560 μg/ml of PLGA-ALE NPs; a significant increase was observed at the highest dilutions. The viability of human umbilical vein endothelial cells and bone marrow stromal cells (BMSC), evaluated through the neutral red test, was not affected by PLGA-ALE NPs. There were no significant differences in cell-associated alkaline phosphatase between BMSC incubated with PLGA-ALE NP- and PBS-added media. These results demonstrated that PLGA-ALE NPs had an acceptable degree of blood compatibility and were not cytotoxic; therefore, they may be considered suitable for intravenous administration.",
keywords = "Bisphosphonate, Blood compatibility, Drug delivery, Nanoparticle, Poly(lactic-co-glycolic acid) copolymer",
author = "Elisabetta Cenni and Donatella Granchi and Sofia Avnet and Caterina Fotia and Manuela Salerno and Dorotea Micieli and Sarpietro, {Maria G.} and Rosario Pignatello and Francesco Castelli and Nicola Baldini",
year = "2008",
month = "4",
doi = "10.1016/j.biomaterials.2007.12.022",
language = "English",
volume = "29",
pages = "1400--1411",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Biocompatibility of poly(d,l-lactide-co-glycolide) nanoparticles conjugated with alendronate

AU - Cenni, Elisabetta

AU - Granchi, Donatella

AU - Avnet, Sofia

AU - Fotia, Caterina

AU - Salerno, Manuela

AU - Micieli, Dorotea

AU - Sarpietro, Maria G.

AU - Pignatello, Rosario

AU - Castelli, Francesco

AU - Baldini, Nicola

PY - 2008/4

Y1 - 2008/4

N2 - Nanoparticles made of a conjugate of poly(d,l-lactide-co-glycolide) with alendronate (PLGA-ALE NPs), were prepared by emulsion/solvent evaporation technique. The conjugation yield, determined by MALDI TOF analysis, was 30-35%. PLGA-ALE NPs size, evaluated by photon correlation spectroscopy, was 198.7 ± 0.2 nm. Haemocompatibility studies using different concentrations of PLGA-ALE NPs did not show any significant effect on haemolysis, leukocyte number, platelet activation, APTT and complement consumption, in comparison with blood incubated with phosphate buffered saline (PBS). A significant reduction of the prothrombin activity was demonstrated after incubation with 560 μg/ml of PLGA-ALE NPs; a significant increase was observed at the highest dilutions. The viability of human umbilical vein endothelial cells and bone marrow stromal cells (BMSC), evaluated through the neutral red test, was not affected by PLGA-ALE NPs. There were no significant differences in cell-associated alkaline phosphatase between BMSC incubated with PLGA-ALE NP- and PBS-added media. These results demonstrated that PLGA-ALE NPs had an acceptable degree of blood compatibility and were not cytotoxic; therefore, they may be considered suitable for intravenous administration.

AB - Nanoparticles made of a conjugate of poly(d,l-lactide-co-glycolide) with alendronate (PLGA-ALE NPs), were prepared by emulsion/solvent evaporation technique. The conjugation yield, determined by MALDI TOF analysis, was 30-35%. PLGA-ALE NPs size, evaluated by photon correlation spectroscopy, was 198.7 ± 0.2 nm. Haemocompatibility studies using different concentrations of PLGA-ALE NPs did not show any significant effect on haemolysis, leukocyte number, platelet activation, APTT and complement consumption, in comparison with blood incubated with phosphate buffered saline (PBS). A significant reduction of the prothrombin activity was demonstrated after incubation with 560 μg/ml of PLGA-ALE NPs; a significant increase was observed at the highest dilutions. The viability of human umbilical vein endothelial cells and bone marrow stromal cells (BMSC), evaluated through the neutral red test, was not affected by PLGA-ALE NPs. There were no significant differences in cell-associated alkaline phosphatase between BMSC incubated with PLGA-ALE NP- and PBS-added media. These results demonstrated that PLGA-ALE NPs had an acceptable degree of blood compatibility and were not cytotoxic; therefore, they may be considered suitable for intravenous administration.

KW - Bisphosphonate

KW - Blood compatibility

KW - Drug delivery

KW - Nanoparticle

KW - Poly(lactic-co-glycolic acid) copolymer

UR - http://www.scopus.com/inward/record.url?scp=38549150276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38549150276&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2007.12.022

DO - 10.1016/j.biomaterials.2007.12.022

M3 - Article

C2 - 18191195

AN - SCOPUS:38549150276

VL - 29

SP - 1400

EP - 1411

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 10

ER -